HENRY KIRORI: Open Payments
NPI 1225816739 · ELKHART, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,388 in 47 payments from 11 companies in 2025. Trend: 2023 $66 · 2024 $1,452 · 2025 $1,388
Food & beverage: $1,388
| Company | Payments | Amount |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 10 | $372 |
| Merck Sharp & Dohme LLC | 12 | $230 |
| AstraZeneca Pharmaceuticals LP | 3 | $195 |
| E.R. Squibb & Sons, L.L.C. | 5 | $176 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $165 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $60 |
| Boston Scientific Corporation | 2 | $54 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | 3 | $53 |
| PFIZER INC. | 3 | $47 |
| Esperion Therapeutics, Inc. | 1 | $18 |
Products named: ONPATTRO, VERQUVO, FARXIGA, CAMZYOS, JARDIANCE, AMVUTTRA, Kerendia, LifeVest.
Industry payments across IN — which companies pay providers there.
